CL2008001669A1 - Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras. - Google Patents
Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras.Info
- Publication number
- CL2008001669A1 CL2008001669A1 CL2008001669A CL2008001669A CL2008001669A1 CL 2008001669 A1 CL2008001669 A1 CL 2008001669A1 CL 2008001669 A CL2008001669 A CL 2008001669A CL 2008001669 A CL2008001669 A CL 2008001669A CL 2008001669 A1 CL2008001669 A1 CL 2008001669A1
- Authority
- CL
- Chile
- Prior art keywords
- dgat
- dyslipidemia
- obesity
- piperidine
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
COMPUESTO INHIBIDOR DE DGAT DE FÓRMULA QUE INCLUYE CUALQUIER FORMA ESTEREOQUÍMICAMENTE ISOMÉRICA DEL MISMO, DONDE A, LA LÍNEA PUNTEADA, X, R, R2 Y R 8 SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA, N-ÓXIDO DE LOS MISMOS, UNA SAL ACEPTABLE PARA USO FARMACÉUTICO DE LOS MISMOS O UN SOLVATO DE LOS MISMOS. ADEMÁS, LA INVENCIÓN SE REFIERE A PROCESOS PARA PREPARAR TALES COMPUESTOS, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDE A DICHOS COMPUESTOS ASÍ COMO AL USO COMO MEDICAMENTO DE DICHOS COMPUESTOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07109865 | 2007-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2008001669A1 true CL2008001669A1 (es) | 2009-07-17 |
Family
ID=38668783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2008001669A CL2008001669A1 (es) | 2007-06-08 | 2008-06-06 | Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras. |
Country Status (10)
Country | Link |
---|---|
US (4) | US8835437B2 (es) |
EP (1) | EP2152271B1 (es) |
JP (1) | JP5443342B2 (es) |
AR (1) | AR067327A1 (es) |
AU (1) | AU2008258549B2 (es) |
CA (1) | CA2687912C (es) |
CL (1) | CL2008001669A1 (es) |
ES (1) | ES2558152T3 (es) |
TW (1) | TWI424997B (es) |
WO (1) | WO2008148840A1 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
NZ555683A (en) | 2004-12-14 | 2010-09-30 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
JP2009520786A (ja) | 2005-12-22 | 2009-05-28 | アストラゼネカ アクチボラグ | Dgat阻害剤として使用するためのピリミド−[4,5−b]−オキサジン |
PL2402319T3 (pl) | 2006-03-31 | 2018-02-28 | Novartis Ag | Inhibitory DGAT |
US8084478B2 (en) | 2006-05-30 | 2011-12-27 | Asstrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
CA2687754C (en) | 2007-06-08 | 2015-12-08 | Janssen Pharmaceutica N.V. | Piperidine, piperazine derivatives for use as dgat inhibitors |
WO2008148840A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
AU2008258560C1 (en) | 2007-06-08 | 2014-04-10 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
PE20100083A1 (es) * | 2008-06-05 | 2010-02-17 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
KR101083421B1 (ko) | 2009-06-23 | 2011-11-14 | 한국과학기술연구원 | 신규 피라졸로이미다졸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 비정상 세포 성장 질환의 예방 및 치료용 약학적 조성물 |
WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
KR101154539B1 (ko) | 2010-04-13 | 2012-06-13 | 한국과학기술연구원 | 신규 아미노피라졸 아릴아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 비정상 세포 성장 질환의 예방 또는 치료용 약학적 조성물 |
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
US8846948B2 (en) * | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
US8716277B2 (en) | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
US9550793B2 (en) | 2012-10-03 | 2017-01-24 | Advinus Therapeutics Limited | Spirocyclic compounds, compositions and medicinal applications thereof |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1383906A (en) | 1971-02-22 | 1974-02-12 | Bdh Pharmaceuticals Ltd | Pyridazinones |
JPS5692887A (en) | 1979-12-05 | 1981-07-27 | Sumitomo Chem Co Ltd | N-substituted imidazole derivative |
DE3338846A1 (de) | 1982-10-29 | 1984-05-03 | Toyama Chemical Co. Ltd., Tokyo | Neue 4-oxo-1,4-dihydronicotinsaeurederivate und salze derselben, verfahren zu ihrer herstellung und antibakterielle mittel mit einem gehalt derselben |
GB8729083D0 (en) | 1987-12-12 | 1988-01-27 | Pfizer Ltd | Triazole antifungal agents |
JP2969359B2 (ja) | 1989-01-13 | 1999-11-02 | 武田薬品工業株式会社 | 環状アミン化合物 |
DE4317093A1 (de) | 1993-05-21 | 1994-11-24 | Basf Ag | Niedermolekulare und polymere flüssigkristalline Benztriazole und deren Verwendung |
TW286317B (es) | 1993-12-13 | 1996-09-21 | Hoffmann La Roche | |
US5639754A (en) * | 1994-07-12 | 1997-06-17 | Janssen Pharmaceutica N.V. | Urea and thiourea derivatives of azolones |
US5637592A (en) * | 1994-07-12 | 1997-06-10 | Janssen Pharmaceutica N.V. | Acyl derivatives of azolones |
FR2722788B1 (fr) | 1994-07-20 | 1996-10-04 | Pf Medicament | Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant |
DE19581346C2 (de) | 1994-09-30 | 1998-04-16 | Hitachi Ltd | Magnetische Aufzeichnungs/Wiedergabevorrichtung |
HUP9602489A3 (en) | 1995-01-11 | 1998-01-28 | Samjin Pharm Co Ltd | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
CA2228136A1 (en) | 1995-08-10 | 1997-02-20 | Merck & Co., Inc. | 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
EP0871444A4 (en) | 1995-08-10 | 1999-01-13 | Merck & Co Inc | 2.5 SUBSTITUTED ARYL PYRROL, THE COMPOSITIONS THAT CONTAIN AND THE USE THEREOF |
GB9702213D0 (en) * | 1996-02-24 | 1997-03-26 | Zeneca Ltd | Chemical compounds |
HN1997000027A (es) | 1996-12-06 | 1997-06-05 | Pfizer Prod Inc | Derivados de 6-fenil piridil - 2 amina |
JPH11139969A (ja) * | 1997-08-07 | 1999-05-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
DE19743435A1 (de) * | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
HUP0102622A3 (en) | 1998-07-20 | 2002-12-28 | Merck Patent Gmbh | Biphenyl derivatives, process for producing them and pharmaceutical compositions containing them |
GB9826412D0 (en) | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
AUPP999799A0 (en) | 1999-04-27 | 1999-05-20 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
CA2374668A1 (en) | 1999-05-21 | 2000-11-30 | Pfizer Products Inc. | New pharmaceutical combinations for nos inhibitors |
NZ515543A (en) * | 1999-06-22 | 2003-11-28 | Neurosearch As | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
MXPA02006016A (es) * | 1999-12-16 | 2002-12-05 | Schering Corp | Imidazoles sustituidos, antagonistas de los receptores y5 del neuropeptido y. |
CA2395648A1 (en) * | 2000-02-10 | 2001-08-16 | Pharmacia & Upjohn Company | Oxazolidinone thioamides with piperazine amide substituents |
GB0013378D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
WO2001095856A2 (en) | 2000-06-15 | 2001-12-20 | Chaconne Nsi Co., Ltd. | Urea derivative useful as an anti-cancer agent and process for preparing same |
US20030060472A1 (en) | 2000-06-21 | 2003-03-27 | Learmonth David Alexander | Novel substituted nitrocatechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them |
GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
AU2002217742B2 (en) | 2001-01-16 | 2008-02-21 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
JO2390B1 (en) | 2001-04-06 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Diphenylcarboxamides act as lipid-lowering agents |
WO2002083134A1 (en) * | 2001-04-12 | 2002-10-24 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
DE10204116A1 (de) | 2002-02-01 | 2003-08-07 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
PL220783B1 (pl) | 2002-03-13 | 2016-01-29 | Janssen Pharmaceutica Nv | Pochodna sulfonylowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna |
ATE521592T1 (de) | 2002-03-13 | 2011-09-15 | Janssen Pharmaceutica Nv | Histone-deacetylase-inhibitoren |
WO2003082864A2 (en) * | 2002-04-01 | 2003-10-09 | Cadila Healthcare Limited | Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them |
TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
US7842693B2 (en) | 2002-06-12 | 2010-11-30 | Chemocentryx, Inc. | Substituted piperazines |
AU2003253141A1 (en) | 2002-08-22 | 2004-03-11 | Orchid Chemicals And Pharmaceuticals Ltd | Novel antibacterial agents |
WO2004047755A2 (en) * | 2002-11-22 | 2004-06-10 | Japan Tobacco Inc. | Fused bicyclic nitrogen-containing heterocycles |
EP1603883B1 (en) | 2003-02-03 | 2012-03-28 | Janssen Pharmaceutica NV | Quinoline-derived amide modulators of vanilloid vr1 receptor |
DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
AR044152A1 (es) | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
US20070099884A1 (en) | 2003-06-06 | 2007-05-03 | Erondu Ngozi E | Combination therapy for the treatment of diabetes |
AU2004257267B2 (en) | 2003-07-14 | 2009-12-03 | Arena Pharmaceuticals,Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
JP4252598B2 (ja) | 2003-08-11 | 2009-04-08 | エフ.ホフマン−ラ ロシュ アーゲー | Or置換フェニル基を有するピペラジン及びglyt1阻害剤としてのこれらの使用 |
JP2005206492A (ja) | 2004-01-21 | 2005-08-04 | Sankyo Co Ltd | スルホンアミド化合物 |
AU2005209115A1 (en) * | 2004-01-30 | 2005-08-11 | Japan Tobacco Inc. | Anorectic compounds |
JP4787529B2 (ja) | 2004-04-09 | 2011-10-05 | 大塚製薬株式会社 | 医薬組成物 |
TW200606137A (en) | 2004-07-02 | 2006-02-16 | Sankyo Co | Urea derivatives |
BRPI0514017A (pt) | 2004-08-03 | 2008-05-27 | Wyeth Corp | indazóis úteis no tratamento de doenças cardiovasculares |
CN100360525C (zh) * | 2004-09-16 | 2008-01-09 | 中国科学院上海药物研究所 | 一类新的噁唑烷酮衍生物、其制备方法和用途 |
CN101084207A (zh) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途 |
GB0421908D0 (en) | 2004-10-01 | 2004-11-03 | Angeletti P Ist Richerche Bio | New uses |
JP2008516978A (ja) | 2004-10-15 | 2008-05-22 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 肥満症の処置のためのビフェニル−4−イル−カルボニルアミノ酸誘導体の製造および使用 |
WO2006047277A2 (en) | 2004-10-22 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Inhibitors of c-fms kinase |
NZ555683A (en) | 2004-12-14 | 2010-09-30 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
JP2008523836A (ja) | 2004-12-22 | 2008-07-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ジアシルグリセロール・アシルトランスフェラーゼのアッセイ |
GT200600046A (es) * | 2005-02-09 | 2006-09-25 | Terapia de combinacion | |
GB0505084D0 (en) | 2005-03-11 | 2005-04-20 | Glaxo Group Ltd | Compounds |
EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
JP2008534664A (ja) | 2005-04-06 | 2008-08-28 | アストラゼネカ アクチボラグ | 置換複素環およびchk1、pdk1及びpak阻害剤としてのそれらの使用 |
EP1874317A4 (en) | 2005-04-19 | 2011-10-26 | Bayer Healthcare Llc | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES IN THE TREATMENT OF OBESITY |
CN100335588C (zh) * | 2005-04-28 | 2007-09-05 | 陈俊光 | 有机硅活性防水粉及其制造方法 |
CA2610188A1 (en) | 2005-06-11 | 2006-12-21 | Astrazeneca Ab | Oxadiazole derivatives as dgat inhibitors |
KR20080028981A (ko) | 2005-06-30 | 2008-04-02 | 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. | Glp-1 약학 조성물 |
JP2007131584A (ja) * | 2005-11-11 | 2007-05-31 | Sankyo Co Ltd | 新規ベンゾオキサゾール誘導体 |
EP1966183A4 (en) | 2005-12-20 | 2010-12-29 | Merck Frosst Canada Ltd | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A-DELTA-9-DESATURASE |
JP2009520786A (ja) | 2005-12-22 | 2009-05-28 | アストラゼネカ アクチボラグ | Dgat阻害剤として使用するためのピリミド−[4,5−b]−オキサジン |
EP1810974A1 (en) | 2006-01-18 | 2007-07-25 | Ludwig-Maximilians-Universität München | Preparation and use of magnesium amides |
TW200804364A (en) | 2006-02-22 | 2008-01-16 | Boehringer Ingelheim Int | New compounds |
US7728031B2 (en) | 2006-02-24 | 2010-06-01 | Abbott Laboratories | Octahydro-pyrrolo[3,4-b]pyrrole derivatives |
JPWO2007102392A1 (ja) | 2006-03-03 | 2009-07-23 | 塩野義製薬株式会社 | Mmp−13選択的阻害剤 |
EP2041132A2 (en) | 2006-07-06 | 2009-04-01 | Boehringer Ingelheim International GmbH | New compounds |
EP1918285A1 (en) | 2006-11-03 | 2008-05-07 | Merck Sante | Diazepane-acetamide derivatives as selective 11beta-HSD1 inhibitors |
GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
BRPI0811947A2 (pt) | 2007-05-22 | 2014-11-11 | Via Pharmaceuticals Inc | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratamento de obesidade, diabetes do tipo ii, dislipidemia ou síndrome metabólica |
AU2008258560C1 (en) | 2007-06-08 | 2014-04-10 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
WO2008148840A1 (en) | 2007-06-08 | 2008-12-11 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
CA2687754C (en) | 2007-06-08 | 2015-12-08 | Janssen Pharmaceutica N.V. | Piperidine, piperazine derivatives for use as dgat inhibitors |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
PE20100083A1 (es) | 2008-06-05 | 2010-02-17 | Janssen Pharmaceutica Nv | Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar |
-
2008
- 2008-06-05 WO PCT/EP2008/056983 patent/WO2008148840A1/en active Application Filing
- 2008-06-05 AU AU2008258549A patent/AU2008258549B2/en not_active Ceased
- 2008-06-05 JP JP2010510800A patent/JP5443342B2/ja active Active
- 2008-06-05 CA CA2687912A patent/CA2687912C/en active Active
- 2008-06-05 US US12/663,009 patent/US8835437B2/en active Active
- 2008-06-05 ES ES08760561.4T patent/ES2558152T3/es active Active
- 2008-06-05 EP EP08760561.4A patent/EP2152271B1/en active Active
- 2008-06-06 TW TW097121018A patent/TWI424997B/zh not_active IP Right Cessation
- 2008-06-06 CL CL2008001669A patent/CL2008001669A1/es unknown
- 2008-06-06 AR ARP080102429A patent/AR067327A1/es unknown
-
2014
- 2014-08-11 US US14/456,054 patent/US9120821B2/en active Active
-
2015
- 2015-07-20 US US14/803,275 patent/US9499567B2/en active Active
-
2016
- 2016-10-13 US US15/292,196 patent/US9688696B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010529084A (ja) | 2010-08-26 |
US20150322088A1 (en) | 2015-11-12 |
AR067327A1 (es) | 2009-10-07 |
JP5443342B2 (ja) | 2014-03-19 |
US9120821B2 (en) | 2015-09-01 |
US8835437B2 (en) | 2014-09-16 |
AU2008258549B2 (en) | 2013-11-14 |
EP2152271A1 (en) | 2010-02-17 |
AU2008258549A1 (en) | 2008-12-11 |
US9499567B2 (en) | 2016-11-22 |
US20140350012A1 (en) | 2014-11-27 |
TW200909430A (en) | 2009-03-01 |
TWI424997B (zh) | 2014-02-01 |
ES2558152T3 (es) | 2016-02-02 |
WO2008148840A1 (en) | 2008-12-11 |
US20170029440A1 (en) | 2017-02-02 |
CA2687912C (en) | 2015-11-03 |
US20100216809A1 (en) | 2010-08-26 |
US9688696B2 (en) | 2017-06-27 |
EP2152271B1 (en) | 2015-10-21 |
CA2687912A1 (en) | 2008-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001669A1 (es) | Compuestos derivados de piperidina/piperazina inhibidora de dgat-1; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento de la obesidad, dislipidemia, fibrosis hepatica y diabetes tipo ii, entre otras. | |
AR072261A1 (es) | Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos. | |
CL2008001671A1 (es) | Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes. | |
PE20181045A1 (es) | Compuestos utiles como inmunomoduladores | |
UY31050A1 (es) | Antagonistas de trpv1 y usos de los mismos | |
CL2011000504A1 (es) | Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer. | |
CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
CL2008002052A1 (es) | Compuestos derivados de pirazol, inhibidores de la 11 beta-hidroxi-esteroide-deshidrogenasa; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y uso para la preparacion de medicamentos para el tratamiento de diabetes, obesidad, trastornos de ingestion de comida o dislipidemia | |
ECSP088747A (es) | Pirazoles como inhibidores de la 11-beta-hsd1 | |
UY32884A (es) | 1-sustituido-4-(5-(fenil o heteroaril)metoxi)-pirimidin-2-il)piperazinas y piperidinas | |
CL2012003211A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas | |
CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
AR071055A1 (es) | Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas | |
EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
CO6230986A2 (es) | Compuesto de 4-piridinona y su uso para cancer | |
CL2008001670A1 (es) | Compuestos derivados de piperidina o piperazina, inhibidores de dgat1; composicion farmaceutica; combinacion farmaceutica; y uso para la prevencion o tratamiento de enfermedades tales como obesidad, hipercolesterolemia, dislipidemia, entre otras. | |
SG10201906942PA (en) | Piperidine cxcr7 receptor modulators | |
AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
ECSP109900A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas | |
CO6270285A2 (es) | Derivados de 4-[(4-amino-1, 3, 5-triazin-2-il)amino]-n-arilmetilcicloalquilcarboxamida | |
AR067770A1 (es) | Derivados de tiazol y ditiazol para el tratamiento de diabetes | |
BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
PH12018500377A1 (en) | Novel annelated benzamides | |
SA518390920B1 (ar) | مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة |